Equillium, Inc. — Q1 2020 Form 10-Q
Business context and reporting period
For the quarter ended March 31, 2020. Equillium is a clinical-stage biotechnology company developing itolizumab (EQ001), a CD6-targeting antibody for severe autoimmune and inflammatory disorders. It has no product sales or other operating revenue and depends on external financing to fund development.
Financial performance and liquidity
| Metric | Q1 2020 / March 31, 2020 | Comparable period / December 31, 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.706 million | $3.759 million in Q1 2019 |
| General and administrative expense | $2.746 million | $2.589 million in Q1 2019 |
| Total operating expenses / loss from operations | $7.452 million / $(7.452) million | $6.348 million / $(6.348) million in Q1 2019 |
| Net loss | $(7.837) million; $(0.45) per share | $(5.950) million; $(0.34) per share in Q1 2019 |
| Cash used in operating activities | $6.370 million | $4.464 million in Q1 2019 |
| Cash and cash equivalents | $20.614 million | $13.219 million |
| Short-term investments | $27.061 million | $39.924 million |
| Total assets / total liabilities | $49.911 million / $13.565 million | $55.539 million / $13.691 million |
| Notes payable | $9.746 million carrying value; $10.0 million principal | $9.681 million carrying value |
Combined cash, cash equivalents and short-term investments were approximately $47.7 million at quarter-end. Management said this was expected to fund planned operations for at least 12 months from the filing date. The company reported no meaningful revenue-based margins because it has no revenue. Current-period operating expense rose about 17% year over year; net loss increased about 32%. Operating cash use increased about 43%.
Material changes, outlook and risks
- R&D expense rose by $0.9 million, mainly from higher clinical development and CRO costs and increased employee compensation, partly offset by lower preclinical and overhead costs. G&A increased by approximately $0.1 million.
- In March, Equillium paused enrollment in its Phase 1b asthma and lupus nephritis trials as a precaution related to COVID-19, not because of observed itolizumab safety issues. Enrollment continued in the Phase 1b/2 acute graft-versus-host disease (aGVHD) trial, although COVID-19 could also disrupt it.
- Management expected aGVHD Phase 1b topline data in the second half of 2020. Trial timing, enrollment, costs and results remained uncertain, particularly given the pandemic.
- The company’s $10 million term loan bears interest at the greater of 8.25% or prime plus 3%, with interest-only payments through June 2021 and principal and interest thereafter; it matures in June 2024. Up to another $10 million is available only if specified clinical milestones are achieved within set time limits. The loan is secured by substantially all assets other than intellectual property, subject to specified exceptions; the company reported covenant compliance at quarter-end.
- Equillium had an ATM facility of up to $8.45 million and a March 2020 purchase agreement allowing up to $15 million of stock sales to Lincoln Park over 36 months. No Lincoln Park shares had been sold by quarter-end. Equity financing may dilute shareholders, and debt and collaboration financing may impose restrictions or require surrendering rights.
- Itolizumab is licensed from Biocon. Potential obligations include up to $30 million in regulatory milestones, up to $565 million in sales milestones, and royalties; none had been paid or received as of March 31. Biocon is also the exclusive clinical supplier and is central to manufacturing, creating supply and execution risks. The company noted Indian export restrictions could affect supply if expanded to cover the drug.
- Subsequent event: on April 22, the board repriced options covering 1,475,093 shares to an exercise price of $2.45. The incremental accounting cost was still being evaluated.
Important facts for investors to verify
- Whether aGVHD trial enrollment and the anticipated topline-data timing were achieved, and the status and restart timing of the paused asthma and lupus nephritis trials.
- Cash burn, available liquidity and financing needs against management’s stated 12-month runway, including any subsequent equity issuance or debt draw.
- Clinical-trial, manufacturing and drug-supply developments involving Biocon, including any impact from COVID-19 or export restrictions.
- The full economic and dilution effects of the loan, ATM and Lincoln Park arrangements, and the accounting impact of the option repricing.
- Milestone, royalty and license diligence obligations to Biocon, which could affect future cash requirements and development rights.
The company reported no legal proceedings and stated that disclosure controls and procedures were effective as of March 31, 2020.